IN2012DN00907A - - Google Patents
Info
- Publication number
- IN2012DN00907A IN2012DN00907A IN907DEN2012A IN2012DN00907A IN 2012DN00907 A IN2012DN00907 A IN 2012DN00907A IN 907DEN2012 A IN907DEN2012 A IN 907DEN2012A IN 2012DN00907 A IN2012DN00907 A IN 2012DN00907A
- Authority
- IN
- India
- Prior art keywords
- protein
- adamts13
- methods
- sample
- cation exchange
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 5
- 102000043853 ADAMTS13 Human genes 0.000 abstract 3
- 108091005670 ADAMTS13 Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 abstract 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 abstract 2
- 101800000620 Disintegrin-like Proteins 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 102000002938 Thrombospondin Human genes 0.000 abstract 1
- 108060008245 Thrombospondin Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 238000005571 anion exchange chromatography Methods 0.000 abstract 1
- 238000005341 cation exchange Methods 0.000 abstract 1
- 238000005277 cation exchange chromatography Methods 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 239000000356 contaminant Substances 0.000 abstract 1
- 238000011026 diafiltration Methods 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000000415 inactivating effect Effects 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
- 239000006228 supernatant Substances 0.000 abstract 1
- 238000000108 ultra-filtration Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/12—Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Sustainable Development (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Water Supply & Treatment (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23030809P | 2009-07-31 | 2009-07-31 | |
| PCT/EP2010/061192 WO2011012726A2 (en) | 2009-07-31 | 2010-08-02 | Method for purifying recombinant adamts13 and other proteins and compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00907A true IN2012DN00907A (en) | 2015-04-03 |
Family
ID=42588355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN907DEN2012 IN2012DN00907A (en) | 2009-07-31 | 2010-08-02 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8945895B2 (en) |
| EP (3) | EP3211077B1 (en) |
| JP (6) | JP5907869B2 (en) |
| KR (7) | KR20230170815A (en) |
| CN (3) | CN102482660A (en) |
| AU (1) | AU2010277491B2 (en) |
| CA (2) | CA2769362A1 (en) |
| CO (1) | CO6612194A2 (en) |
| DK (1) | DK2459715T3 (en) |
| EA (3) | EA201992487A1 (en) |
| ES (3) | ES2763207T3 (en) |
| HR (1) | HRP20192303T1 (en) |
| HU (1) | HUE046909T2 (en) |
| IN (1) | IN2012DN00907A (en) |
| LT (1) | LT2459715T (en) |
| MX (2) | MX348178B (en) |
| NZ (2) | NZ620988A (en) |
| PL (2) | PL2459715T3 (en) |
| PT (1) | PT2459715T (en) |
| SG (2) | SG178175A1 (en) |
| SI (1) | SI2459715T1 (en) |
| WO (1) | WO2011012726A2 (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008113011A2 (en) | 2007-03-14 | 2008-09-18 | Ligocyte Pharmaceuticals, Inc. | Virus like particle purification |
| FR2918375B1 (en) * | 2007-07-05 | 2009-10-16 | Lab Francais Du Fractionnement | USE OF A CHROMATOGRAPHY MEDIUM TO REDUCE THE QUANTITY OF ADAMTS13 IN A PLASMA-DERIVED SOLUTION |
| US8945895B2 (en) * | 2009-07-31 | 2015-02-03 | Baxter International Inc. | Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof |
| CN103917655B (en) * | 2011-03-14 | 2016-05-25 | 康泰伦特药物解决方案有限责任公司 | Decorin compositions and uses thereof |
| WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| WO2013028330A2 (en) | 2011-08-19 | 2013-02-28 | Emd Millipore Corporation | Methods of reducing level of one of more impurities in a sample during protein purification |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| AU2013277532B2 (en) * | 2012-06-21 | 2017-06-15 | Takeda Pharmaceutical Company Limited | Virus filtration of cell culture media |
| JOP20130186B1 (en) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | Purification of virus like particles |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| EP2890782A1 (en) | 2012-09-02 | 2015-07-08 | AbbVie Inc. | Methods to control protein heterogeneity |
| HK1214622A1 (en) * | 2013-01-09 | 2016-07-29 | Takeda Pharmaceutical Company Limited | Methods for purification of arylsulfatase a |
| CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US8946395B1 (en) * | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| US8859252B1 (en) | 2014-01-02 | 2014-10-14 | Aerial Biopharma, Llc | Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same |
| KR102567586B1 (en) | 2014-02-04 | 2023-08-16 | 바이오젠 엠에이 인코포레이티드 | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| AU2017307582C1 (en) | 2016-08-04 | 2021-05-06 | Takeda Pharmaceutical Company Limited | Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome |
| CA3080656A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| JP2021519339A (en) * | 2018-04-03 | 2021-08-10 | メルク パテント ゲーエムベーハー | Low-salt elution of target protein from CEX chromatography medium and biopharmaceutical feedstock |
| KR102140531B1 (en) * | 2018-08-07 | 2020-08-04 | (주)휴온스 | The processing method of Gly-Tβ4 |
| KR20210149117A (en) * | 2019-04-03 | 2021-12-08 | 젠자임 코포레이션 | Continuous Production of Recombinant Proteins |
| EP4037704B1 (en) | 2019-10-04 | 2025-12-03 | The Children's Medical Center Corporation | Adamts13 treatment to enhance graft survival |
| US11821000B2 (en) * | 2020-11-10 | 2023-11-21 | Dionex Corporation | Method of separating viral vectors |
| WO2023052556A1 (en) * | 2021-09-30 | 2023-04-06 | Ichnos Sciences SA | Methods of inactivating viral contaminants with a mixture of solvent and detergent |
| CN118891279A (en) | 2022-03-07 | 2024-11-01 | 武田药品工业株式会社 | Affinity chromatography production of clinical human IgG products |
| CN119173254A (en) * | 2022-05-10 | 2024-12-20 | 株式会社绿十字 | Novel liquid preparation of plasma proteins |
| TW202400224A (en) * | 2022-05-10 | 2024-01-01 | 南韓商綠十字股份有限公司 | A novel liquid formulation for lyophilization of plasma protein |
| WO2025181559A1 (en) * | 2024-02-29 | 2025-09-04 | Sloiron, Inc. | Methods for determining the amount of encapsulated and free iron in a sample |
| US20250334572A1 (en) * | 2024-04-26 | 2025-10-30 | Waters Technologies Corporation | Host cell protein detection using lateral flow devices |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239854A (en) * | 1978-04-24 | 1980-12-16 | Sumitomo Chemical Company, Limited | Enzyme-immobilization carriers and preparation thereof |
| US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| US5283182A (en) * | 1986-09-17 | 1994-02-01 | Beecham Group Plc | Preparation of immobilized hydantoinase stabilized with divalent metal ions |
| CA1339946C (en) | 1987-03-31 | 1998-07-07 | Michael J. Griffith | Ultrapurification process for polypeptides |
| US5792835A (en) * | 1991-09-05 | 1998-08-11 | Baxter International Inc. | Method of preparing a topical fibrinogen complex |
| FR2681867B1 (en) | 1991-09-26 | 1993-12-31 | Pasteur Merieux Serums Vaccins | FACTOR VIII PURIFICATION PROCESS AND PREPARATIONS OBTAINED. |
| FR2686899B1 (en) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| WO1993017724A1 (en) | 1992-03-02 | 1993-09-16 | Bioeng, Inc. | Viral inactivation method |
| US5296228A (en) * | 1992-03-13 | 1994-03-22 | Allergan, Inc. | Compositions for controlled delivery of pharmaceutical compounds |
| US5288853A (en) | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
| US5578480A (en) * | 1993-04-23 | 1996-11-26 | American Cyanamid Company | Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris |
| GB9503750D0 (en) * | 1995-02-24 | 1995-04-12 | Common Services Agency | Thrombin preparation |
| US5688912A (en) | 1995-09-22 | 1997-11-18 | Bayer Corporation | Peptide ligands which bind to von willebrand factor |
| US5786458A (en) * | 1996-06-28 | 1998-07-28 | Bayer Corporation | Selective stabilization of protein during viral inactivation |
| US5831003A (en) | 1996-06-28 | 1998-11-03 | Bayer Corporation | Peptides which bind to prothrombin and thrombin |
| US7141393B2 (en) * | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
| US6429192B1 (en) | 1998-06-10 | 2002-08-06 | Statens Serum Institut | Purification process for production of mannan-binding lectin and an MBL medicinal product |
| US6251860B1 (en) * | 1998-07-07 | 2001-06-26 | Suomen Punainen Risti Veripalvelu | Pharmaceutical preparations |
| US6214221B1 (en) | 1999-02-22 | 2001-04-10 | Henry B. Kopf | Method and apparatus for purification of biological substances |
| US6451978B2 (en) * | 2000-01-21 | 2002-09-17 | Biovitrum Ab | Purification of antithrombin-III-α and β |
| IL136552A (en) | 2000-06-05 | 2005-05-17 | Omrix Biopharmaceuticals Ltd | Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration |
| JPWO2002031163A1 (en) * | 2000-10-11 | 2004-02-19 | 財団法人かずさディー・エヌ・エー研究所 | Novel ADAMTS family polypeptide and gene encoding the same |
| US6926894B2 (en) | 2000-11-22 | 2005-08-09 | Baxter Aktiengesellschaft | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
| CN1230526C (en) * | 2001-02-27 | 2005-12-07 | 成都夸常科技有限公司 | Method for removing organic solvent used as virus inactivator and/or detergent |
| US7037658B2 (en) * | 2001-08-16 | 2006-05-02 | Regents Of University Of Michigan | Methods and compositions for detecting variant ADAMTS13 genes |
| JP2003144154A (en) * | 2001-11-14 | 2003-05-20 | Mitsubishi Pharma Corp | Novel ADAMTS family polypeptide and gene encoding the same |
| IL158297A0 (en) * | 2001-12-05 | 2004-05-12 | Cangene Corp | Pharmaceutical compositions containing immune globulin and methods for the preparation thereof |
| DE60231651D1 (en) | 2001-12-21 | 2009-04-30 | Immunex Corp | PROTEIN CLEANING PROCESS |
| US20030133829A1 (en) | 2001-12-21 | 2003-07-17 | Baxter Healthcare Corporation | Process for inactivating pathogens in a biological material |
| GB0216002D0 (en) * | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
| GB0216001D0 (en) | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
| US7718763B2 (en) * | 2002-10-18 | 2010-05-18 | Japan As Represented By The President Of National Cardiovascular Center | Substrate polyeptides for von Willebrand factor cleaving protease ADAMTS-13 |
| US20060134706A1 (en) | 2003-07-09 | 2006-06-22 | Michihiro Hide | Atopic dermatitis inducer |
| CA2487673C (en) * | 2003-12-02 | 2010-11-02 | F. Hoffmann-La Roche Ag | Improved method for the recombinant production and purification of protein kinases |
| GB0405330D0 (en) * | 2004-03-10 | 2004-04-21 | Astrazeneca Ab | Enzyme and preparation method |
| WO2005099858A1 (en) * | 2004-04-13 | 2005-10-27 | Sangart, Inc. | Methods and compositions for simultaneously isolating hemoglobin from red blood cells and inactivating viruses |
| AU2005252296B2 (en) | 2004-06-07 | 2009-08-20 | Evolve Biologics Inc. | Isolation of plasma or serum proteins |
| US7270976B2 (en) | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
| US7515392B2 (en) | 2004-07-28 | 2009-04-07 | Texas Instruments Incorporated | High voltage circuits implemented using low voltage transistors |
| DE102004044419B4 (en) * | 2004-09-14 | 2010-04-15 | Biotest Ag | Process for the purification of a von Willebrand factor by means of hydroxylapatite continuous chromatography |
| JP2006083044A (en) | 2004-09-17 | 2006-03-30 | Hitachi Ltd | Glass member |
| CA2592888A1 (en) * | 2005-01-05 | 2006-07-13 | Foundation For Fatal Rare Diseases | Pharmaceutically active antiviral peptides |
| US20060193966A1 (en) * | 2005-02-28 | 2006-08-31 | Shaowen Wu | Multi-anion treated soy proteins and methods for preparation thereof |
| US20070015703A1 (en) | 2005-06-17 | 2007-01-18 | Denisa Wagner | ADAMTS13-containing compositions having thrombolytic activity |
| FR2887883B1 (en) | 2005-06-29 | 2007-08-31 | Lab Francais Du Fractionnement | PROCESS FOR SEPARATING FIBRINOGEN PROTEINS, FACTOR XIII AND BIOLOGICAL GLUE OF SOLUBILIZED PLASMA FRONTION AND PREPARATION OF LYOPHILIZED CONCENTRATES OF SAID PROTEINS |
| US7506514B2 (en) | 2005-06-30 | 2009-03-24 | United Technologies Corporation | Augmentor fuel conduit bushing |
| CA2632714A1 (en) * | 2005-12-07 | 2007-06-14 | Technische Universitaet Muenchen | Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins |
| JP5067917B2 (en) | 2005-12-28 | 2012-11-07 | アルフレッサファーマ株式会社 | Separation and purification method of ADAMTS13 |
| EP1990421B1 (en) | 2006-02-16 | 2012-06-13 | Mitsubishi Chemical Medience Corporation | Method of detecting condition in patient with disturbance of consciousness |
| US7468258B2 (en) | 2006-03-07 | 2008-12-23 | Wake Forest University Health Sciences | Self-quenching homofluorophore compositions for detecting enzyme activity |
| WO2008057074A1 (en) * | 2006-11-06 | 2008-05-15 | Millipore Corporation | Method of flow-through chromatography |
| JP5505853B2 (en) | 2007-02-13 | 2014-05-28 | 味の素株式会社 | Virus inactivation method using slightly acidic arginine as an additive |
| EP2374878B1 (en) * | 2007-06-22 | 2015-08-19 | The Chemo-Sero-Therapeutic Research Institute | Novel adamts-13 mutant |
| FR2918375B1 (en) * | 2007-07-05 | 2009-10-16 | Lab Francais Du Fractionnement | USE OF A CHROMATOGRAPHY MEDIUM TO REDUCE THE QUANTITY OF ADAMTS13 IN A PLASMA-DERIVED SOLUTION |
| PL2167526T3 (en) | 2007-07-11 | 2011-09-30 | Novo Nordisk As | Purification of factor viii using a mixed-mode or multimodal resin |
| JP5570989B2 (en) * | 2007-08-31 | 2014-08-13 | アムジエン・インコーポレーテツド | Solid protein formulation |
| US20090130714A1 (en) * | 2007-09-24 | 2009-05-21 | Reliance Life Sciences Pvt.Ltd. | Process for purifying recombinanat tissue plasminogen activator (TPA) |
| US8945895B2 (en) * | 2009-07-31 | 2015-02-03 | Baxter International Inc. | Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof |
-
2010
- 2010-07-30 US US12/847,956 patent/US8945895B2/en active Active
- 2010-08-02 WO PCT/EP2010/061192 patent/WO2011012726A2/en not_active Ceased
- 2010-08-02 AU AU2010277491A patent/AU2010277491B2/en active Active
- 2010-08-02 EA EA201992487A patent/EA201992487A1/en unknown
- 2010-08-02 SI SI201031958T patent/SI2459715T1/en unknown
- 2010-08-02 EA EA201270214A patent/EA023783B1/en not_active IP Right Cessation
- 2010-08-02 JP JP2012522191A patent/JP5907869B2/en active Active
- 2010-08-02 NZ NZ620988A patent/NZ620988A/en unknown
- 2010-08-02 LT LTEP10737917.4T patent/LT2459715T/en unknown
- 2010-08-02 KR KR1020237042089A patent/KR20230170815A/en not_active Ceased
- 2010-08-02 PL PL10737917T patent/PL2459715T3/en unknown
- 2010-08-02 EP EP17155619.4A patent/EP3211077B1/en active Active
- 2010-08-02 CA CA2769362A patent/CA2769362A1/en not_active Abandoned
- 2010-08-02 ES ES10737917T patent/ES2763207T3/en active Active
- 2010-08-02 EA EA201500952A patent/EA034292B1/en not_active IP Right Cessation
- 2010-08-02 PL PL17155619.4T patent/PL3211077T3/en unknown
- 2010-08-02 EP EP10737917.4A patent/EP2459715B1/en active Active
- 2010-08-02 ES ES23210110T patent/ES3039686T3/en active Active
- 2010-08-02 HU HUE10737917A patent/HUE046909T2/en unknown
- 2010-08-02 CN CN2010800370780A patent/CN102482660A/en active Pending
- 2010-08-02 MX MX2014008412A patent/MX348178B/en unknown
- 2010-08-02 PT PT107379174T patent/PT2459715T/en unknown
- 2010-08-02 CA CA2916508A patent/CA2916508A1/en not_active Abandoned
- 2010-08-02 KR KR1020187021317A patent/KR20180087463A/en not_active Ceased
- 2010-08-02 ES ES17155619T patent/ES3000382T3/en active Active
- 2010-08-02 KR KR1020197031048A patent/KR20190122272A/en not_active Ceased
- 2010-08-02 MX MX2012001263A patent/MX2012001263A/en active IP Right Grant
- 2010-08-02 SG SG2012006581A patent/SG178175A1/en unknown
- 2010-08-02 NZ NZ597756A patent/NZ597756A/en unknown
- 2010-08-02 CN CN201711191958.3A patent/CN107988192A/en active Pending
- 2010-08-02 DK DK10737917.4T patent/DK2459715T3/en active
- 2010-08-02 EP EP23210110.5A patent/EP4299735B1/en active Active
- 2010-08-02 HR HRP20192303TT patent/HRP20192303T1/en unknown
- 2010-08-02 KR KR1020207036716A patent/KR20200146042A/en not_active Ceased
- 2010-08-02 KR KR1020177022447A patent/KR101883610B1/en active Active
- 2010-08-02 SG SG2013066824A patent/SG193855A1/en unknown
- 2010-08-02 KR KR1020227016072A patent/KR20220066435A/en not_active Ceased
- 2010-08-02 CN CN201710433159.6A patent/CN107267490A/en active Pending
- 2010-08-02 KR KR1020127004995A patent/KR101769634B1/en active Active
- 2010-08-02 IN IN907DEN2012 patent/IN2012DN00907A/en unknown
-
2012
- 2012-02-14 CO CO12025851A patent/CO6612194A2/en unknown
-
2014
- 2014-12-16 US US14/571,670 patent/US11661593B2/en active Active
-
2015
- 2015-05-25 JP JP2015105808A patent/JP6216930B2/en active Active
-
2016
- 2016-09-30 JP JP2016194640A patent/JP2016222724A/en not_active Withdrawn
-
2018
- 2018-10-03 JP JP2018188301A patent/JP2018203781A/en not_active Withdrawn
-
2020
- 2020-10-16 JP JP2020174837A patent/JP2021004265A/en active Pending
-
2022
- 2022-09-21 JP JP2022150048A patent/JP2022171925A/en active Pending
-
2023
- 2023-04-11 US US18/298,742 patent/US12492390B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN00907A (en) | ||
| JP2013500711A5 (en) | ||
| CY1123952T1 (en) | ISOLATION AND PURIFICATION OF ANTI-IL-13 ANTIBODIES USING PROTEIN A Affinity Chromatography | |
| MX2007003906A (en) | Methods and compositions for improving recombinant protein production. | |
| CY1120768T1 (en) | METHOD FOR CLEANING PROCARIATIC VARIABLES OF THE AMMONIA SOLUTION OF PHENYLALANINE | |
| SG157346A1 (en) | Improved purification of collagenases from clostridium histolyticum liquid culture | |
| PE20150720A1 (en) | PURIFICATION OF IDURONATE-2-SULFATASE | |
| WO2008085962A3 (en) | Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants | |
| WO2010048192A3 (en) | Viral inactivation during purification of antibodies | |
| MX2011011454A (en) | Plants having enhanced yield-related traits and a method for making the same. | |
| HK1206756A1 (en) | Modulated lysine variant species compositions and methods for producing and using the same | |
| DK0891420T3 (en) | Method for replication of influenza virus in cell culture as well as the influenza virus obtainable by the method | |
| EA201591807A1 (en) | METHODS OF MANUFACTURING SAMPLES TO CONTROL THE CONTENT OF C-END LYSIN, GALACTOSE AND SIALIC ACID IN RECOMBINANT PROTEINS | |
| WO2011097381A8 (en) | Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof | |
| WO2012024400A3 (en) | Elution of proteins from hydroxyapatite resins without resin deterioration | |
| CA2551345C (en) | Process for separating fibrinogen proteins, factor xiii and biological glue from a soluble plasma fraction and for preparing lyophilized concentrates of the said proteins | |
| WO2006113475A3 (en) | Methods and compositions to modulate adhesion and stress tolerance in bacteria | |
| BRPI1013956A2 (en) | method for isolating a recombinant protein, spray dried particles, composition, and method for reducing oxalate absorption. | |
| WO2007041213A3 (en) | Methods for regulation of p53 translation and function | |
| WO2008073617A3 (en) | Increasing tolerance of plants to low light conditions | |
| ATE496133T1 (en) | AFFINITY POLYPEPTIDE FOR PURIFYING RECOMBINANT PROTEINS | |
| EP2067857A4 (en) | PROCESS FOR PRODUCING DIPEPTIDE | |
| WO2006091535A3 (en) | Novel egg receptors for sperm proteins | |
| WO2007149570A3 (en) | Modulation of protein levels in plants | |
| ATE451457T1 (en) | METHOD FOR PRODUCING DIPEPTIDE |